Ivan Kruljac graduated from the University of Zagreb School of Medicine in 2010 and earned his PhD from the same institution in 2016. His doctoral research was the first in the world to address the clinical question: “Is ketosis in patients with type 2 diabetes a positive or negative prognostic marker?”
He gained his clinical experience at the “Mladen Sekso” Department of Endocrinology, Diabetes and Metabolic Diseases at the Sestre milosrdnice University Hospital Center, where he worked as a ward physician and head of the Neuroendocrine Tumor Board.
His scientific work includes approximately 60 published articles in international peer-reviewed journals, including papers in some of the world’s most prestigious medical journals such as The New England Journal of Medicine and The American Journal of Medicine. He was a co-founder and executive editor of the journal Endocrine Oncology and Metabolism, which during his tenure was indexed in internationally recognized databases such as DOAJ, EMBASE, and SCOPUS, and registered with ICMJE and COPE.
From 2019 to 2020, he was the secretary of the Croatian Society for Endocrinology and as Croatia’s representative in the European Society of Endocrinology. In 2024, he was awarded the title of Assistant Professor at the School of Medicine, Catholic University of Croatia.
Ivan Kruljac is the co-founder and director of Solmed Polyclinic, a company specializing in clinical trial implementation, where he has served as a Principal Investigator in 8 international clinical trials, providing study medication for more than 250 patients. He is also the founder of the Metabolic Friendly platform, the first medical center in the region specialized in metabolism, where he remains actively involved in the diagnosis and treatment of patients with insulin resistance as the head of the Metabolic Friendly board.
